Modis Therapeutics Competitors and Similar CompaniesClear all

Modis Therapeutics's competitors and similar companies include Amicus Therapeutics, Bluebird Bio, Ultragenyx and VCANBIO.
Modis Therapeutics
Modis Therapeutics
Modis Therapeutics develops treatments for rare genetic diseases.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
Ultragenyx
Ultragenyx
Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
VCANBIO
VCANBIO
VCANBIO Cell & Gene Engineering (also known as Zhongyuan Union) is a biotech company that offers health management services and products.
Founding Date
Founding Date
2016
Founding Date
2002
Founding Date
1992
Founding Date
2010
Founding Date
1993
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Oakland, US HQ
Locations
Philadelphia, US HQ
Northbridge, AU
Pointe Claire, CA
Paris, FR
München, DE
Dublin, IE
Milano, IT
see more
Locations
Somerville, US HQ
Locations
Novato, US HQ
Buenos Aires, AR
São Paulo, BR
Bogotá, CO
Paris, FR
Berlin, DE
Tokyo, JP
see more
Locations
Tianjin, CN HQ
Employees
Employees
109% decrease
Employees
58415% increase
Employees
32338% decrease
Employees
1,2763% decrease
Employees
2,0149% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
3.4 b
Valuation ($)
95.4 m
Valuation ($)
4.9 b
Valuation ($)
1.4 b

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$634.2m (FY, 2025)
Revenue (est.)
$83.8m (FY, 2024)
Revenue (est.)
$673m (FY, 2025)
Revenue (est.)
¥1.4b (FY, 2025)
Cost of goods
Cost of goods
N/A
Cost of goods
$72.9m (FY, 2025)
Cost of goods
$89.4m (FY, 2024)
Cost of goods
N/A
Cost of goods
¥438.8m (FY, 2025)
Gross profit
Gross profit
N/A
Gross profit
$561.3m (FY, 2025)
Gross profit
($5.6m) (FY, 2024)
Gross profit
N/A
Gross profit
¥993.4m (FY, 2025)
Net income
Net income
N/A
Net income
($27.1m) (FY, 2025)
Net income
($240.7m) (FY, 2024)
Net income
($575m) (FY, 2025)
Net income
¥103.5m (FY, 2025)

Funding

Total funding raised
Total funding raised
$ 30m
Total funding raised
$ 88m
Total funding raised
$ 409m
Total funding raised
$ 200.1m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Amicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.

View company
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease

Bluebird Bio is a developer of gene therapies for severe genetic diseases.

View company
Ultragenyx
HQ
Novato, US
Employees
1,276↓ 3% decrease

Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.

View company
VCANBIO
HQ
Tianjin, CN
Employees
2,014↓ 9% decrease

VCANBIO Cell & Gene Engineering (also known as Zhongyuan Union) is a biotech company that offers health management services and products.

View company